GSK plc: updates and filings

GSKNYSEHealthcare · Pharmaceutical Preparations

Price

$47.76

November 20, 2026Market cap $96.7B

What Ploutos Investor adds for GSK

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 11 fiscal years, from 2015
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 6, 2026 latest annual
  • Nov 20, 2026Current report (foreign company)
    Form6-K
  • Nov 19, 2026Current report (foreign company)
    Form6-K
  • Nov 18, 2026Current report (foreign company)
    Form6-K
  • Nov 17, 2026Current report (foreign company)
    Form6-K
  • Nov 13, 2026Current report (foreign company)
    Form6-K
  • Nov 12, 2026Current report (foreign company)
    Form6-K
  • Nov 6, 2026Current report (foreign company)
    Form6-K
  • Nov 5, 2026Its own holdings as an investment manager (13F)
    Form13F-HR
  • Nov 2, 2026Current report (foreign company)
    Form6-K
  • Oct 28, 2026Current report (foreign company)
    Form6-K
  • Oct 26, 2026Current report (foreign company)
    Form6-K
  • Oct 26, 2026Current report (foreign company)
    Form6-K
  • Oct 26, 2026Current report (foreign company)
    Form6-K
  • Oct 26, 2026Current report (foreign company)
    Form6-K
  • Oct 21, 2026Current report (foreign company)
    Form6-K
  • Oct 19, 2026Current report (foreign company)
    Form6-K
  • Oct 19, 2026Current report (foreign company)
    Form6-K
  • Oct 15, 2026Current report (foreign company)
    Form6-K
  • Oct 14, 2026Current report (foreign company)
    Form6-K
  • Oct 13, 2026Shares registered for employees
    FormS-8
  • Oct 13, 2026Current report (foreign company)
    Form6-K
  • Oct 13, 2026Current report (foreign company)
    Form6-K
  • Oct 8, 2026Current report (foreign company)
    Form6-K
  • Oct 6, 2026Current report (foreign company)
    Form6-K
  • Oct 1, 2026Current report (foreign company)
    Form6-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC since Jan 12, 2001: every report, 8-K, meeting and letter. Of its other filings (6,672 in all), the newest.

The full analysis

What do GSK's filings show?

The filings are where every one of GSK's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.